Personalis, Inc. (NASDAQ:PSNL) Position Cut by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in Personalis, Inc. (NASDAQ:PSNL) by 10.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 792,608 shares of the company’s stock after selling 92,809 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Personalis were worth $4,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PSNL. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after purchasing an additional 4,504 shares in the last quarter. nVerses Capital LLC bought a new position in Personalis during the 3rd quarter valued at $40,000. International Assets Investment Management LLC boosted its stake in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after purchasing an additional 17,082 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Personalis during the 1st quarter valued at $29,000. Finally, Virtu Financial LLC bought a new position in Personalis during the 1st quarter valued at $41,000. 61.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on PSNL. Needham & Company LLC reaffirmed a “buy” rating and set a $7.25 price target on shares of Personalis in a research note on Thursday, November 7th. HC Wainwright increased their price objective on Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Finally, BTIG Research increased their price objective on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a research report on Friday, August 16th.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $3.59 on Tuesday. Personalis, Inc. has a one year low of $1.12 and a one year high of $7.20. The stock has a fifty day moving average of $5.03 and a 200-day moving average of $3.49. The company has a market capitalization of $253.63 million, a PE ratio of -2.14 and a beta of 1.94.

Personalis (NASDAQ:PSNL) last released its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The business had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same quarter in the previous year, the company earned ($0.51) EPS. As a group, research analysts forecast that Personalis, Inc. will post -1.33 EPS for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.